• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Secondary malignancies following cancer chemotherapy.

作者信息

Boffetta P, Kaldor J M

机构信息

International Agency for Research on Cancer, Lyon, France.

出版信息

Acta Oncol. 1994;33(6):591-8. doi: 10.3109/02841869409121767.

DOI:10.3109/02841869409121767
PMID:7946433
Abstract

Many agents used in cancer chemotherapy are known carcinogens. However, few secondary malignancies have been definitely linked to chemotherapy, since studies on this problem are complicated by methodological problems. A causal relationship has been established between alkylating agents and leukaemia and between cyclophosphamide and bladder cancer. The risk of leukaemia peaks at 5-10 years after beginning of chemotherapy and declines steadily after its end. The interaction between chemotherapy and radiotherapy has not been fully clarified, nor has the leukaemogenic potency of individual drugs, although combinations without nitrogen mustard seem to entail a lower risk. Other tumours reported at increased incidence, in particular among Hodgkin's disease patients, for whom a carcinogenic effect of chemotherapy seems plausible, are non-Hodgkin's lymphoma and lung cancer. Other secondary solid tumors have also been reported, but for none of them an independent effect of chemotherapy has been demonstrated.

摘要

相似文献

1
Secondary malignancies following cancer chemotherapy.
Acta Oncol. 1994;33(6):591-8. doi: 10.3109/02841869409121767.
2
Treatment of testicular cancer and the development of secondary malignancies.睾丸癌的治疗与继发性恶性肿瘤的发生
J Clin Oncol. 1995 Jan;13(1):283-92. doi: 10.1200/JCO.1995.13.1.283.
3
Secondary transitional cell carcinoma and nitrogen mustard treatment.
Urology. 2005 Jun;65(6):1226-7. doi: 10.1016/j.urology.2004.12.037.
4
Incidence of second cancers in patients treated for Hodgkin's disease.霍奇金淋巴瘤患者继发癌症的发病率。
J Natl Cancer Inst. 1995 May 17;87(10):732-41. doi: 10.1093/jnci/87.10.732.
5
Therapy-related malignancies following treatment of germ cell cancer.生殖细胞癌治疗后的治疗相关恶性肿瘤。
Int J Cancer. 1999 Dec 10;83(6):860-3. doi: 10.1002/(sici)1097-0215(19991210)83:6<860::aid-ijc32>3.0.co;2-l.
6
Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.霍奇金淋巴瘤按治疗类型划分的第二原发性癌症风险:对英国国家淋巴瘤调查中2846例患者的分析
BMJ. 1992 May 2;304(6835):1137-43. doi: 10.1136/bmj.304.6835.1137.
7
Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study.
Eur J Haematol. 2000 Aug;65(2):123-7. doi: 10.1034/j.1600-0609.2000.90218.x.
8
Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.环磷酰胺治疗非霍奇金淋巴瘤后发生的膀胱癌和肾癌。
J Natl Cancer Inst. 1995 Apr 5;87(7):524-30. doi: 10.1093/jnci/87.7.524.
9
The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.一项病例对照研究表明,接受霍奇金淋巴瘤联合治疗方案的患者发生急性白血病的风险显著高于单纯接受化疗的患者,且该风险与放疗范围、化疗类型及疗程相关。
Haematologica. 1998 Sep;83(9):812-23.
10
The incidence of secondary leukemias.继发性白血病的发病率。
Haematologica. 1999 Oct;84(10):937-45.

引用本文的文献

1
Harnessing p53 for targeted cancer therapy: new advances and future directions.利用p53进行靶向癌症治疗:新进展与未来方向。
Transcription. 2025 Feb;16(1):3-46. doi: 10.1080/21541264.2025.2452711. Epub 2025 Mar 3.
2
Cancer survivorship road map.癌症幸存者路线图。
Can Fam Physician. 2024 Jul-Aug;70(7-8):465-468. doi: 10.46747/cfp.700708465.
3
MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines.MDR1 抑制逆转了六株多柔比星耐药犬前列腺和膀胱癌细胞系的多柔比星耐药性。
Int J Mol Sci. 2023 May 2;24(9):8136. doi: 10.3390/ijms24098136.
4
Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response.基于分子 MRI 的癌症免疫治疗反应监测。
Int J Mol Sci. 2023 Feb 5;24(4):3151. doi: 10.3390/ijms24043151.
5
Incidence of second primary malignancies in women with different stages of breast cancer.处于不同乳腺癌分期的女性中第二原发性恶性肿瘤的发病率。
Front Oncol. 2023 Jan 9;12:1047684. doi: 10.3389/fonc.2022.1047684. eCollection 2022.
6
Revisiting Epithelial Carcinogenesis.重新审视上皮性肿瘤发生。
Int J Mol Sci. 2022 Jul 4;23(13):7437. doi: 10.3390/ijms23137437.
7
Cisplatin Reduces the Frequencies of Radiotherapy-Induced Micronuclei in Peripheral Blood Lymphocytes of Patients with Gynaecological Cancer: Possible Implications for the Risk of Second Malignant Neoplasms.顺铂降低妇科癌症患者外周血淋巴细胞放疗诱导微核的频率:对第二恶性肿瘤风险的可能影响。
Cells. 2021 Oct 9;10(10):2709. doi: 10.3390/cells10102709.
8
Second primary malignancies in colorectal cancer patients.结直肠癌患者的第二原发恶性肿瘤。
Sci Rep. 2021 Feb 2;11(1):2759. doi: 10.1038/s41598-021-82248-7.
9
Genomic Adaption and Mutational Patterns in a HaCaT Subline Resistant to Alkylating Agents and Ionizing Radiation.烷基化剂和电离辐射抗性 HaCaT 亚系中的基因组适应和突变模式。
Int J Mol Sci. 2021 Jan 24;22(3):1146. doi: 10.3390/ijms22031146.
10
Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers.吸烟相关及非吸烟相关癌症患者发生第二原发癌的风险。
J Cancer Res Clin Oncol. 2020 Jul;146(7):1765-1779. doi: 10.1007/s00432-020-03232-8. Epub 2020 Apr 30.